Compared to idarubicin, GO when added to FLAG based frontline induction/consolidation regimen results in better early molecular responses and improved relapse free survival in CBF AML. Click and hear Gautam Borthakur present the new data. ...

In this MEDtalk John F. Seymour present the key data from MURANO study. Venetoclax (Ven) is a highly selective oral inhibitor of BCL2, a key regulator of the intrinsic apoptotic pathway, which is constitutively overexpressed in CLL. Efficacy and safety of VenR given for a fixed duration in R/R CLL was evaluated in the randomized ...

Both the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) and the CD3-CD19 bispecific T-cell engager blinatumomab have single-agent activity in relapsed or refractory acute lymphoblastic leukemia (ALL). We previously reported the promising efficacy and survival of INO in combination with low-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL. In this MEDtalk Nicholas J. Short ...

Real-world evidence from the Belgian registry shows that ponatinib has a favorable efficacy and safety profile in, and supports its use in CML and Ph+ ALL patients who are resistant or intolerant to previous therapies or those with the T315I mutation. Deep molecular responses were obtained in the majority of patients. No new safety signals ...

In this MEDtalk Guy Young present data from HAVEN 2 – the largest prospective study in pediatric PwHA with inhibitors to date. HAVEN 2 demonstrates that emicizumab prophylaxis is well tolerated and can prevent or substantially reduce bleeds in this population. Meaningful efficacy and PK were maintained with less frequent dosing, with no new safety ...

In this MEDtalk John Gribben, Professor, MD DSc, Barts Cancer Institute, University of London, present the key data from MURANO study about treatment of relapsed/Refractory CLL. ...

#Senaste tidskrift

Lungmedicin

Nr. 25 • mars 2019
årgång 5
  • KOL
  • Luftvägsinfektion